Policy

Poland to ban MON810 maize
Enlarge image

BusinessPoland

Poland to ban MON810 maize

16.04.2012 - The Polish government is to ban Monsanto's MON810 maize making it the seventh in the club of EU countries to stop cultivation of the GM crop.

Warsaw – The move follows protests in Warsaw last month by around 1,500 beekeepers and anti-GM protesters who dumped thousands of dead bees on the steps of the Ministry of Agriculture. Agriculture Minister Marek Sawicki has announced that the government would implement a ban on the cultivation of the genetically modified MON 810 maize. The minister claimed the pollen might be responsible for a host of health problems and may even be the cause of the dwindling bee population. The government now wants to pass a law that circumvents the need to obtain EU approval for a ban on any GMO crops. Revised Polish regulations would stipulate that the ban may be implemented and that it will suffice simply to notify the European Commission of the matter. “We are pleasantly surprised that the government is looking for a way of actually implementing the ban,” said Greenpeace spokesman Jacek Winiarski after having a discussion with governmental representatives. If Poland implements the ban, it will follow in the footsteps of Austria, France, Germany, Greece, Hungary and Luxembourg which have all banned the cultivation of MON 810 at different stages, saying it threatens biodiversity.

http://www.european-biotechnology-news.com/news/news/2012-02/poland-imposes-ban-on-gmos.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

    FLOP

      TOP

        FLOP

          TOP

            FLOP

              No liability assumed, Date: 26.11.2014